BN Business News
Add your company to Business Communicator →

Business · 23/12/2020Updated: 10/17/2026 · 1 min read

Endo Pharmaceuticals Withdraws New Drug Application for OPANA ER Tablets

Summary

The FDA is withdrawing approval of Endo Pharmaceuticals' new drug application for OPANA ER tablets, a request made by the company itself, after waiving its right to a hearing.

Original source language: Federal Register — Food and Drug AdministrationOpen original release →

Explore insights

Business insights →